This market resolves to Yes if the National Institute for Health and Care Excellence (NICE) officially approves pirtobrutinib (Jaypirca) for the treatment of chronic lymphocytic leukaemia by June 15, 2026. Pirtobrutinib is recommended for patients who have already been treated with a covalent Bruton’s tyrosine kinase inhibitor and for whom further covalent BTKi treatment is not suitable.